In summary, our work reveals that the combination of intranodal administration of DRibb-les derived from either autologous or allogeneic mammary cancer and anti-OX40 co-stimulation could induce cross-reactive T-cell immune responses and tumor regression in mice bearing established 4T1 tumors. The gene discussed is TNFRSF4; the disease is neoplasm.